Editorial: Jupiter or Aurora? Micro-inflammation and dyslipidaemia: Twin targets for statin therapy in CKD

International Urology and Nephrology

Volumn 42, Issue 1, 2010, Pages 133-136

  Goldsmith, David ^a   Covic, Adrian C ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN;

ANALYTICAL RESEARCH; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DYSLIPIDEMIA; EDITORIAL; EVIDENCE BASED PRACTICE; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PUBLICATION; PUBLISHING; RENAL REPLACEMENT THERAPY; RISK FACTOR; CHRONIC DISEASE; INFLAMMATION; KIDNEY DISEASE;

CHRONIC DISEASE; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; KIDNEY DISEASES;

EID: 77950868012     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-009-9649-3     Document Type: Editorial

References (17)

1. Kanbay M, Covic A, Goldsmith DJA (2009) Dyslipidemia in chronic kidney disease and renal transplant patients-A review of the evidence for benefit versus harm. J Nephrol 22:598-609
2. P Stenvinkel JJ Carrero J Alexsson B Lindholm O Heimburger Z Massy 2008 Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? CJASN 3 2 505 521 1:CAS:528:DC%2BD1cXhtVWlt73F 18184879
3. AY Wang 2005 Prognostic value of C-reactive protein for heart disease in dialysis patients Curr Opinion Invest Drugs 6 9 879 886 1:CAS:528: DC%2BD2MXhtVyksbfE (Pubitemid 41269367)
4. M Chmielewski JJ Carrero L Nordfors B Lindholm P Stenvinkel 2008 Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach J Nephrol 21 635 644 1:CAS:528:DC%2BD1MXmtVOkurY%3D 18949717
5. R Agarwal AD Sinha 2009 Cardiovascular protection with antihypertensive drugs in dialysis. Patients systematic review and meta-analysis Hypertension 53 860 10.1161/HYPERTENSIONAHA.108.128116 1:CAS:528:DC%2BD1MXksFeisbk%3D 19273737
6. A Covic P Gusbeth-Tatomir D Goldsmith 2008 Negative outcome studies in end stage renal disease: how dark are the storm clouds? Nephrol Dial Transplant 23 1 56 61 10.1093/ndt/gfm706 18032412 (Pubitemid 351767425)
7. C Wanner V Krane W März, et al. 2005 Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 3 238 248 10.1056/NEJMoa043545 1:CAS:528:DC%2BD2MXmt1Kms7s%3D 16034009 (Pubitemid 41058323)
8. Krane V, Winkler K, Dreschler C et al (2008) Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74(11):1461-1467
9. GF Strippoli SD Navaneethan DW Johnson, et al. 2008 Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials BMJ 22;336 7645 645 651 10.1136/bmj.39472.580984.AE (Pubitemid 351481234)
10. B Fellström H Holdaas AG Jardine, et al. 2009 Rosuvastatin and cardiovascular events in patients undergoing haemodialysis N Engl J Med 360 14 1395 1407 10.1056/NEJMoa0810177 19332456
11. PM Ridker E Danielson FA Fonseca, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein NEJM 359 21 2195 2207 10.1056/NEJMoa0807646 1:CAS:528:DC%2BD1cXhtl2gurnL 18997196
12. CM Yu Q Zhang L Lam H Lin SL Kong W Chan JW Fung KK Cheng IH Chan SW Lee JE Sanderson CW Lam 2007 Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease Heart 93 8 933 939 10.1136/hrt.2006.102848 1:CAS:528:DC%2BD2sXpsFartL4%3D 17344325 (Pubitemid 47122042)
13. DJ Betteridge JM Gibson PT Sager 2007 Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study) Am J Cardiol 100 8 1245 1248 10.1016/j.amjcard.2007.05.044 1:CAS:528: DC%2BD2sXhtFCjsLfI 17920365 (Pubitemid 47505225)
14. T Pearson C Ballantyne C Sisk A Shah E Veltri D Maccubbin 2007 Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing creactive protein and low-density lipoprotein cholesterol levels Am J Cardiol. 99 12 1706 1713 10.1016/j.amjcard.2007.01.062 1:CAS:528: DC%2BD2sXmt1yhtbw%3D 17560879 (Pubitemid 46874325)
15. G Stoll M Bendszus 2006 Inflammation and atherosclerosis: novel insights into plaque formation and destabilization Stroke 37 7 1923 1932 10.1161/01.STR.0000226901.34927.10 1:CAS:528:DC%2BD28XmtVShu7c%3D 16741184 (Pubitemid 44297753)
16. Silverstein DM (2008) Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Paediatr Nephrol 24:1445-1452
17. M Landray C Baigent C Leaper, et al. 2006 The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD Am J Kidney Dis 47 3 385 395 10.1053/j.ajkd.2005.11.018 1:CAS:528:DC%2BD28XivVCku7g%3D 16490616 (Pubitemid 43255171)